文献速递炎症性肠病

可转移的IgA包被内脏臭味杆菌限制结肠炎症

Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation.
PubMed 文献 · Gastroenterology · 2021-10-02

该研究对60例接受FMT治疗活动性UC的供体和受体样本进行宏基因组分析和菌株追踪,并结合IgA-seq和小鼠定植实验。发现应答者中存在可转移的核心供体菌株,内脏臭味杆菌与临床应答及黏膜调节性T细胞诱导相关,并可通过增加Foxp3+/RORγt+ Treg、诱导IL-10和产生短链脂肪酸来限制小鼠结肠炎。

要点

  • 供体来源的可转移菌株可预测UC患者对FMT的临床应答
  • 内脏臭味杆菌与FMT应答及黏膜调节性T细胞诱导相关
  • 该菌通过Treg、IL-10和短链脂肪酸依赖性机制限制小鼠结肠炎

核心结论

  • 首次发现与UC患者FMT临床应答相关的可转移供体来源菌株,内脏臭味杆菌是促进代谢和免疫保护以限制结肠炎的关键组分。

研究设计与样本

  • 对60例接受FMT治疗活动性UC的供体和受体样本进行宏基因组分析和菌株追踪,并用IgA-seq定义免疫反应性菌群。
  • 将患者来源菌株定植于无菌或基因工程小鼠以确定微生物影响肠道免疫的机制。

主要发现

  • 宏基因组分析确定了达到临床应答的UC受者中核心供体来源可转移细菌菌株,并在独立FMT治疗UC试验中预测应答。
  • 对FMT受者样本和定植供体菌群的无菌小鼠进行IgA-seq,识别出内脏臭味杆菌为塑造黏膜免疫的可转移菌株,与临床应答和黏膜调节性T细胞诱导相关。
  • 小鼠定植内脏臭味杆菌导致Foxp3+/RORγt+调节性T细胞增加、IL-10诱导和短链脂肪酸产生,这些均为该菌限制小鼠结肠炎所需。

临床怎么用

  • 可考虑将供体来源可转移菌株特征用于预测或增强UC患者FMT疗效。
  • 内脏臭味杆菌及其代谢和免疫机制可作为微生物治疗UC的靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is an emerging treatment modality for ulcerative colitis (UC). Several randomized controlled trials have shown efficacy for FMT in the treatment of UC, but a better understanding of the transferable microbiota and their immune impact is needed to develop more efficient microbiome-based therapies for UC. METHODS: Metagenomic analysis and strain tracking was performed on 60 donor and recipient samples receiving FMT for active UC. Sorting and sequencing of immunoglobulin (Ig) A-coated microbiota (called IgA-seq) was used to define immune-reactive microbiota. Colonization of germ-free or genetically engineered mice with patient-derived strains was performed to determine the mechanism of microbial impact on intestinal immunity. RESULTS: Metagenomic analysis defined a core set of donor-derived transferable bacterial strains in UC subjects achieving clinical response, which predicted response in an independent trial of FMT for UC. IgA-seq of FMT recipient samples and gnotobiotic mice colonized with donor microbiota identified Odoribacter splanchnicus as a transferable strain shaping mucosal immunity, which correlated with clinical response and the induction of mucosal regulatory T cells. Colonization of mice with O splanchnicus led to an increase in Foxp3+/RORγt+ regulatory T cells, induction of interleukin (IL) 10, and production of short chain fatty acids, all of which were required for O splanchnicus to limit colitis in mouse models. CONCLUSIONS: This work provides the first evidence of transferable, donor-derived strains that correlate with clinical response to FMT in UC and reveals O splanchnicus as a key component promoting both metabolic and immune cell protection from colitis. These mechanistic features will help enable strategies to enhance the efficacy of microbial therapy for UC. Clinicaltrials.gov ID NCT02516384.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Lima SF, Gogokhia L, Viladomiu M, et al. Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation. Gastroenterology. 2021. PMID: 34606847. doi:10.1053/j.gastro.2021.09.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。